文献速递基础与转化研究新药、器械与细胞基因治疗研发

靶向人紧密连接蛋白6的RNA编码T细胞衔接双特异性抗体的临床前疗效与药代动力学

Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6.
PubMed 文献 · Sci Transl Med · 2024-05-22

本文报道了BNT142的临床前药理学:这是一种脂质纳米颗粒(LNP)配制的RNA(RNA-LNP),编码能单价结合T细胞标志物CD3、二价结合紧密连接蛋白6(CLDN6)的T细胞衔接双特异性抗体。在细胞培养、小鼠和食蟹猴中,RNA被翻译并自组装分泌为功能性双特异性抗体RiboMab02.1,体外介导CLDN6靶细胞特异性T细胞活化和增殖及强效靶细胞杀伤。小鼠和食蟹猴静脉给药后维持治疗性血清浓度,小鼠中编码抗体在循环中维持时间比直接注射相同序列蛋白更长;小鼠每周注射0.1至1 μg BNT142 RNA-LNP足以消除CLDN6阳性皮下人异种移植瘤并较对照延长生存,肿瘤消退伴随T细胞浸润和CLDN6阳性细胞耗竭。CLDN6阳性荷瘤小鼠人源化外周血单个核细胞(PBMC)后,BNT142仅诱导短暂低水平细胞因子产生,小鼠和食蟹猴未观察到不良效应体征。基于这些发现,已启动1/2期首次人体临床试验评估BNT142 RNA-LNP在CLDN6阳性晚期实体瘤患者中的安全性和初步疗效(NCT05262530)。

要点

  • BNT142 RNA-LNP在细胞、小鼠和食蟹猴中翻译分泌功能性双特异性抗体RiboMab02.1。
  • 小鼠每周0.1至1 μg BNT142 RNA-LNP足以消除CLDN6阳性皮下人异种移植瘤并较对照延长生存。
  • 小鼠和食蟹猴未观察到BNT142 RNA-LNP给药相关不良效应体征。

核心结论

  • BNT142 RNA-LNP在临床前模型中显示抗CLDN6阳性肿瘤活性,并已启动1/2期首次人体临床试验(NCT05262530)评估其安全性和初步疗效。

研究设计与样本

  • 临床前药理学研究,在细胞培养、小鼠和食蟹猴中评估BNT142 RNA-LNP的翻译、分泌、体外功能、体内药代动力学、抗肿瘤疗效和安全性。

主要发现

  • 体外RiboMab02.1介导CLDN6靶细胞特异性T细胞活化和增殖及强效靶细胞杀伤。
  • 小鼠和食蟹猴静脉给予BNT142 RNA-LNP后维持编码抗体的治疗性血清浓度。
  • 小鼠中RNA编码RiboMab02.1在循环中维持时间比直接注射序列相同蛋白更长。
  • 小鼠每周注射0.1至1 μg BNT142 RNA-LNP足以消除CLDN6阳性皮下人异种移植瘤并较对照延长生存,肿瘤消退伴随T细胞浸润和CLDN6阳性细胞耗竭。
  • CLDN6阳性荷瘤小鼠经PBMC人源化后,BNT142仅诱导短暂低水平细胞因子产生;小鼠和食蟹猴未观察到不良效应体征。

关键数值与推荐

  • 小鼠每周注射BNT142 RNA-LNP剂量范围为0.1至1 μg。
  • 已启动1/2期首次人体临床试验(NCT05262530),评估BNT142 RNA-LNP在CLDN6阳性晚期实体瘤患者中的安全性和初步疗效。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present the preclinical pharmacology of BNT142, a lipid nanoparticle (LNP)-formulated RNA (RNA-LNP) encoding a T cell-engaging bispecific antibody that monovalently binds the T cell marker CD3 and bivalently binds claudin 6 (CLDN6), an oncofetal antigen that is absent from normal adult tissue but expressed on various solid tumors. Upon BNT142 RNA-LNP delivery in cell culture, mice, and cynomolgus monkeys, RNA is translated, followed by self-assembly into and secretion of the functional bispecific antibody RiboMab02.1. In vitro, RiboMab02.1 mediated CLDN6 target cell-specific activation and proliferation of T cells, and potent target cell killing. In mice and cynomolgus monkeys, intravenously administered BNT142 RNA-LNP maintained therapeutic serum concentrations of the encoded antibody. Concentrations of RNA-encoded RiboMab02.1 were maintained longer in circulation in mice than concentrations of directly injected, sequence-identical protein. Weekly injections of mice with BNT142 RNA-LNP in the 0.1- to 1-μg dose range were sufficient to eliminate CLDN6-positive subcutaneous human xenograft tumors and increase survival over controls. Tumor regression was associated with an influx of T cells and depletion of CLDN6-positive cells. BNT142 induced only transient and low cytokine production in CLDN6-positive tumor-bearing mice humanized with peripheral blood mononuclear cells (PBMCs). No signs of adverse effects from BNT142 RNA-LNP administration were observed in mice or cynomolgus monkeys. On the basis of these and other findings, a phase 1/2 first-in-human clinical trial has been initiated to assess the safety and preliminary efficacy of BNT142 RNA-LNP in patients with CLDN6-positive advanced solid tumors (NCT05262530).

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Stadler CR, Ellinghaus U, Fischer L, et al. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6. Sci Transl Med. 2024. PMID: 38776391. doi:10.1126/scitranslmed.adl2720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。